Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1791 |
Name | peritoneal carcinoma |
Definition | A peritoneum cancer that is located_in the inside of the abdomen. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer peritoneum cancer peritoneal carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00565851 | Phase III | Gemcitabine Docetaxel + Paclitaxel Carboplatin Bevacizumab | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 2 |
NCT00954174 | Phase III | Carboplatin + Paclitaxel Ifosfamide + Paclitaxel | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer | Unknown status | USA | 1 |
NCT00989651 | Phase I | Bevacizumab + Veliparib Carboplatin Paclitaxel Cisplatin | Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT00993655 | Phase III | Cisplatin Paclitaxel Carboplatin | Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Completed | USA | GBR | ESP | CAN | 0 |
NCT01012817 | Phase Ib/II | Topotecan + Veliparib | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT01031381 | Phase II | Bevacizumab + Everolimus | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer | Completed | USA | 0 |
NCT01061515 | Phase I | Capecitabine Bevacizumab Oxaliplatin | Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT01132014 | Phase I | Bevacizumab Dacarbazine | Autologous OC-DC Vaccine in Ovarian Cancer | Completed | USA | 0 |
NCT01145430 | Phase I | Pegylated liposomal doxorubicin + Veliparib | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | Completed | USA | 0 |
NCT01146795 | Phase II | Bevacizumab + Carboplatin + Paclitaxel | Neoadjuvant Therapy for Ovarian Cancer | Completed | USA | 0 |
NCT01239732 | Phase III | Bevacizumab + Carboplatin + Paclitaxel | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | Completed | TUR | SWE | SVN | SVK | ROU | POL | NLD | LVA | LTU | ITA | ISR | IRL | HUN | GRC | FRA | EST | ESP | DNK | CHE | CAN | BRA | BGR | AUT | ARG | 13 |
NCT01248962 | Phase II | Carboplatin | Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer | Completed | USA | 0 |
NCT01264432 | Phase I | Veliparib | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | Completed | USA | CAN | 0 |
NCT01281514 | Phase I | Carboplatin + Everolimus + Pegylated liposomal doxorubicin | Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | Completed | USA | 0 |
NCT01305213 | Phase Ib/II | Fosbretabulin Bevacizumab | Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | Completed | USA | 0 |
NCT01312376 | Phase I | Fludarabine Cyclophosphamide Bevacizumab CD3/CD28 stimulated/primed autologous Ts OC-DC vaccine | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | Terminated | USA | 0 |
NCT01357161 | Phase II | Carboplatin Adavosertib Paclitaxel | A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | Completed | 0 | |
NCT01445418 | Phase I | Olaparib Carboplatin | AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer | Completed | USA | 0 |
NCT01459380 | Phase I | Carboplatin Doxorubicin Veliparib Bevacizumab | Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Completed | USA | 0 |
NCT01493505 | Phase III | Carboplatin Paclitaxel Trebananib | TRINOVA-3 | Terminated | USA | NLD | ITA | GRC | ESP | DNK | DEU | CAN | BEL | AUT | 4 |
NCT01519869 | Phase I | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | Completed | USA | 0 | |
NCT01535157 | Phase Ib/II | Ketoconazole Fenretinide | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | Terminated | USA | 0 |
NCT01579812 | Phase II | Metformin | Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients | Completed | USA | 0 |
NCT01607905 | Phase I | Selinexor | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | USA | DNK | CAN | 0 |
NCT01652079 | Phase II | Bevacizumab + NLG207 | CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer | Completed | USA | 0 |
NCT01669798 | Phase II | Nintedanib | BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | Completed | USA | 0 |
NCT01849874 | Phase III | Binimetinib | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Terminated | USA | SWE | POL | NOR | NLD | ITA | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS | 0 |
NCT01936974 | Phase II | Bevacizumab + Cisplatin + Gemcitabine Bevacizumab + Gemcitabine + Oxaliplatin Bevacizumab + Carboplatin + Gemcitabine Bevacizumab + Gemcitabine | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma | Terminated | USA | 0 |
NCT01974765 | Phase II | Enzalutamide | Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies | Completed | USA | 0 |
NCT02050009 | Phase I | Carboplatin + Metformin + Paclitaxel | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |
NCT02059265 | Phase II | Dasatinib | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | Terminated | USA | 0 |
NCT02091999 | Phase I | Enfortumab vedotin-ejfv | A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | Completed | USA | CAN | 0 |
NCT02101775 | Phase II | Gemcitabine Adavosertib + Gemcitabine | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | CAN | 1 |
NCT02101788 | Phase II | Topotecan Letrozole + Paclitaxel + Pegylated liposomal doxorubicin + Tamoxifen Trametinib | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | Active, not recruiting | USA | GBR | 0 |
NCT02121990 | Phase I | Bevacizumab + Cisplatin + Olaparib + Paclitaxel | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | Completed | USA | 0 |
NCT02122185 | Phase II | Metformin Carboplatin + Docetaxel + Paclitaxel | Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT02166905 | Phase Ib/II | Poly ICLC Rasdegafusp alfa Epacadostat | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | Completed | USA | 0 |
NCT02188550 | Phase II | Everolimus + Letrozole | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | Unknown status | USA | 0 |
NCT02208375 | Phase Ib/II | Capivasertib + Olaparib Olaparib + Vistusertib | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | Active, not recruiting | USA | 0 |
NCT02275039 | Phase I | MVAp53 Gemcitabine | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | Completed | USA | 0 |
NCT02283658 | Phase II | Everolimus + Letrozole | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | Completed | USA | 0 |
NCT02312245 | Phase II | Topotecan Doxorubicin Paclitaxel Gemcitabine | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Completed | USA | 0 |
NCT02316834 | Phase I | Talazoparib | POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer | Completed | USA | 0 |
NCT02392676 | Phase III | Olaparib | Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations | Withdrawn | USA | GBR | 3 |
NCT02431559 | Phase Ib/II | Aldoxorubicin + Durvalumab + Motolimod | A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated | Completed | USA | CHE | 0 |
NCT02440425 | Phase II | Paclitaxel Pembrolizumab | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | Completed | USA | 0 |
NCT02446600 | Phase III | Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | CAN | 2 |
NCT02459301 | Phase I | Monalizumab | Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin | Completed | CAN | 0 |
NCT02470585 | Phase III | Carboplatin Paclitaxel Veliparib | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated | USA | POL | NZL | ISR | GBR | ESP | DNK | BRA | AUS | 2 |
NCT02485990 | Phase Ib/II | Olaparib Tremelimumab | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | Terminated | USA | 0 |
NCT02537444 | Phase II | Acalabrutinib Pembrolizumab | ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191) | Completed | USA | 0 |
NCT02571725 | Phase Ib/II | Olaparib + Tremelimumab | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02608684 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer | Completed | USA | 0 |
NCT02657928 | Phase II | Letrozole + Ribociclib | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | Completed | USA | 0 |
NCT02659241 | Phase I | Adavosertib | A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02661815 | Phase I | Paclitaxel + Ricolinostat Bevacizumab | A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer | Terminated | USA | 0 |
NCT02764333 | Phase II | Durvalumab + TPIV 200 | TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer | Completed | USA | 0 |
NCT02833506 | Phase I | NY-ESO-1 peptide vaccine + Sirolimus NY-ESO-1 peptide vaccine | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |
NCT02834975 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | Terminated | USA | 0 |
NCT02889900 | Phase II | Cediranib + Olaparib | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO) | Completed | USA | 0 |
NCT02901899 | Phase II | Guadecitabine + Pembrolizumab | Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Completed | USA | 0 |
NCT02922764 | Phase I | RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 | A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma | Completed | USA | 0 |
NCT02953457 | Phase II | Durvalumab + Olaparib + Tremelimumab | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation | Completed | USA | 0 |
NCT03017131 | Phase I | Aldesleukin + Cyclophosphamide + Decitabine + Letetresgene autoleucel | Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
NCT03029403 | Phase II | Cyclophosphamide + Maveropepimut-S + Pembrolizumab | Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Active, not recruiting | CAN | 0 |
NCT03038100 | Phase III | Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050) | Completed | USA | TUR | SWE | POL | NOR | ITA | ISR | GRC | FRA | FIN | ESP | DNK | DEU | CZE | BRA | BEL | AUT | AUS | 4 |
NCT03054298 | Phase I | HuCART-meso cells Cyclophosphamide | CAR T Cells in Mesothelin Expressing Cancers | Completed | USA | 0 |
NCT03054909 | Phase I | Nogapendekin alfa inbakicept | QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer | Completed | USA | 0 |
NCT03079687 | Expanded access | Olaparib | Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Approved for marketing | USA | 0 |
NCT03134638 | Phase I | Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | Terminated | USA | FRA | CAN | 0 |
NCT03162562 | Phase I | Oregovomab + Poly ICLC | The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | Terminated | USA | 0 |
NCT03206047 | Phase Ib/II | Atezolizumab + Guadecitabine Atezolizumab Atezolizumab + Guadecitabine + Rasdegafusp alfa | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT03206645 | Phase I | Carboplatin + Paclitaxel + Unesbulin | PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy | Completed | USA | 0 |
NCT03246074 | Phase I | Fostamatinib + Paclitaxel | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | Completed | USA | 0 |
NCT03278717 | Phase III | Olaparib Cediranib + Olaparib | Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients (ICON9) | Unknown status | NZL | GBR | CAN | AUS | 0 |
NCT03319628 | Phase I | XMT-1536 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | Active, not recruiting | USA | 0 |
NCT03348631 | Phase II | Tazemetostat | Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT03355976 | Phase II | Ipilimumab + Nivolumab Nivolumab | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | Active, not recruiting | USA | 0 |
NCT03394885 | Phase Ib/II | Atezolizumab + Carboplatin + Paclitaxel | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (AdORN) | Completed | USA | 0 |
NCT03410784 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer (MITO28MaNGOov4) | Unknown status | ITA | 0 |
NCT03462342 | Phase II | Ceralasertib + Olaparib | Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI) | Active, not recruiting | USA | 0 |
NCT03531645 | Phase II | Fulvestrant + Palbociclib | Fulvestrant Plus Palbociclib in Women With Advanced Low Grade Serous Carcinoma | Active, not recruiting | USA | 0 |
NCT03596281 | Phase I | Pegylated liposomal doxorubicin + Pembrolizumab Bevacizumab + Pembrolizumab | Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer (PEMBOV) | Completed | FRA | 0 |
NCT03598270 | Phase III | Carboplatin + Gemcitabine Niraparib Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Atezolizumab + Niraparib | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA) | Completed | ITA | FRA | ESP | DEU | BEL | 0 |
NCT03673124 | Phase II | Letrozole + Ribociclib | Ribociclib and Letrozole Treatment in Ovarian Cancer | Unknown status | USA | 0 |
NCT03691376 | Phase I | Melphalan NY-ESO-1 TCR CD4- CD34+ HSC Aldesleukin Autologous NY-ESO-1-specific CD8-positive T cells | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated | USA | 0 |
NCT03734692 | Phase Ib/II | Cisplatin + Pembrolizumab + Rintatolimod | Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | Recruiting | USA | 0 |
NCT03735589 | Phase Ib/II | alphaDC1 + NK-like CTLs | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |
NCT03839524 | Phase I | TG4050 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | Completed | USA | FRA | 0 |
NCT03924245 | Phase Ib/II | Entinostat Entinostat + Olaparib | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | Terminated | USA | 0 |
NCT04095364 | Phase III | Carboplatin + Letrozole + Paclitaxel Letrozole | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer | Recruiting | USA | IRL | CAN | 2 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04498117 | Phase III | Carboplatin + Oregovomab + Paclitaxel Carboplatin + Paclitaxel | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5) | Active, not recruiting | USA | ITA | HUN | ESP | CZE | CAN | BRA | BEL | ARG | 5 |
NCT04516447 | Phase I | Azenosertib + Pegylated liposomal doxorubicin Azenosertib + Carboplatin | A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer | Recruiting | USA | BGR | AUS | 4 |
NCT04570839 | Phase Ib/II | BMS-986207 + COM701 + Nivolumab Nivolumab | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | Completed | USA | 0 |
NCT04625270 | Phase II | Defactinib + RO5126766 RO5126766 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (RAMP 201) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | 0 |
NCT04657068 | Phase Ib/II | ART0380 + Gemcitabine ART0380 Gemcitabine | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT04706962 | Phase I | TH1902 | TH1902 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT04787289 | Phase II | Bevacizumab | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer | Recruiting | CAN | 0 |
NCT04887961 | Phase II | Pegylated liposomal doxorubicin + Trabectedin | Reprab Study: PLD + Trabectedin Rechallenge (MITO36) | Unknown status | ITA | 0 |
NCT04918186 | Phase II | BA3021 + Durvalumab Durvalumab + Mecbotamab Vedotin | Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC) | Recruiting | USA | CAN | 0 |
NCT05032040 | Phase II | XmAb20717 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | Active, not recruiting | USA | 0 |
NCT05116189 | Phase III | Bevacizumab + Docetaxel Bevacizumab + Paclitaxel + Pembrolizumab Bevacizumab + Docetaxel + Pembrolizumab Bevacizumab + Paclitaxel | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | Active, not recruiting | USA | TUR | POL | NZL | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | DNK | DEU | CAN | BRA | BEL | AUS | 7 |
NCT05199272 | Phase Ib/II | 23ME-00610 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT05257408 | Phase III | Nab-paclitaxel Nab-paclitaxel + Relacorilant | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | Active, not recruiting | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | CAN | BRA | BEL | AUS | ARG | 1 |
NCT05261490 | Phase Ib/II | Pegylated liposomal doxorubicin + TTI-622 | Study of TTI-622 in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | Terminated | USA | 0 |
NCT05358639 | Phase I | Navitoclax + Olaparib | Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | Active, not recruiting | CAN | 0 |
NCT05394675 | Phase I | DS-9606a | A Study of DS-9606a in Patients With Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
NCT05465941 | Phase II | PLX038 | PLX038 for the Treatment of Patients With Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | Recruiting | USA | 0 |
NCT05564377 | Phase II | Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Recruiting | USA | 1 |
NCT05601700 | Phase III | Carboplatin + Paclitaxel Letrozole | Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (LEPRE) | Recruiting | ITA | 0 |
NCT05601752 | Phase II | ADP-A2M4CD8 | ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3) | Active, not recruiting | USA | GBR | FRA | ESP | CAN | 0 |
NCT05636111 | Phase I | Bevacizumab + Lurbinectedin + Paclitaxel | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | Recruiting | USA | 0 |
NCT05739981 | Phase II | Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + GEN-1 + Paclitaxel | A Phase II Study Evaluating the Effect of GEN-1 on SLL When Administered in Combination With Bevacizumab and NACT in Subjects Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (MRD) | Recruiting | USA | 0 |
NCT05756907 | Phase Ib/II | Atezolizumab + SON-1010 SON-1010 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | Recruiting | USA | AUS | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 1 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05961124 | Phase II | Niraparib | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | Recruiting | CAN | 0 |
NCT05983276 | Phase II | Carboplatin + Decitabine + Paclitaxel + Selinexor Carboplatin + Decitabine + Paclitaxel | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | Recruiting | USA | 0 |
NCT06028932 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients | Recruiting | USA | 0 |
NCT06065462 | Phase Ib/II | Dostarlimab-gxly + LB-100 | Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 | Recruiting | USA | 0 |
NCT06136884 | Phase I | AO-252 | A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06334432 | Phase Ib/II | NUV-1511 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06483048 | Phase I | Autologous MUC1-activated T-cells Cyclophosphamide Bendamustine | MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer | Recruiting | USA | 0 |
NCT06617923 | Phase II | Senaparib + Temozolomide | Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer | Recruiting | USA | 0 |
NCT06639074 | Phase II | FRalphaDC vaccine | Folate Receptor Alpha Dendritic Cells (FRalphaDCs) or Placebo for the Treatment of Patients with Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial | Recruiting | USA | 0 |
NCT06824467 | Phase III | SKB264 Bevacizumab + SKB264 Bevacizumab | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | Recruiting | USA | 3 |